Interventions: Concentrations of AMH, progesterone, and estradiol were measured in the serum on cycle day 3 (d3) and on the day of oocyte pickup (dOPU), and in FF. Cycles were sorted into 3 sets of 3 distinct groups according to whether serum d3, serum dOPU, and FF AMH concentrations were </=30 th centile (low AMH), between the 31 st and the 70 th centile (average AMH) or >70 th centile (high AMH) of measurements.
Introduction
Growing evidence indicates that anti-Müllerian hormone (AMH), a glycoprotein that is exclusively produced by the granulosa cells of ovarian follicles in the adult female (1) , is a unique biomarker of the ovarian follicular status. In contrast with inhibin B and estradiol, AMH is produced, presumably FSH-independently (2, 3) , in a wide range of follicles that goes from the primary to the small antral stages of folliculogenesis (4) (5) (6) . In line with this, on cycle day 3, peripheral AMH levels have shown greater sensitivity to ovarian ageing (7) , stronger relationship with the number of early antral follicles (8) , and improved cycle-to-cycle reproducibility (9) , as compared to inhibin B, estradiol, and FSH levels. In addition, serum AMH levels are a useful predictor of the ovarian response to controlled ovarian hyperstimulation (COH) (10) (11) (12) .
Yet, the possible relationship between AMH production by an individual follicle and its functional quality (i.e. follicle aptitude to release an oocyte able to become a developing embryo) remains to be demonstrated. Indeed, previous studies conducted in different species as the rat (4), the sheep (13) , and humans (6) have shown that granulosa cells from atretic follicles fail to express AMH. In addition, in regularly ovulating women, AMH content in individual follicles is related to both the number of early antral follicles on day 3 and their responsiveness to COH (14) . These data indicate that women endowed with more antral follicles may also show increased per-follicle AMH levels, which implicitly suggests that peripheral AMH levels reflect not only antral follicle count but also per-follicle AMH production. Since direct information on the relationship between per-follicle AMH production and the outcome of the oocyte/embryo still is lacking, new insights into this sensitive issue could help to clarifying the role of AMH as a qualitative indicator of ovarian follicular status.
The present study was then conducted to investigate the possible relationship between AMH concentrations, measured both in the serum and in the follicular fluid (FF), and the fate of oocytes and embryos generated in IVF-ET conducted in monodominant follicle cycles. Indeed, contrary to COH, in this modality of treatment, a single follicle achieves preovulatory maturation and only one oocyte and embryo are obtained. This may be particularly instrumental in investigating this issue as it allows the adequate traceability between the single follicle and the ensuing oocyte and embryo. 
Materials and Methods

Subjects
Serum and follicular fluid collection
On dOPU, women underwent a blood sampling by venipuncture at approximately 9 AM.
Sera were separated and frozen in aliquots at -80 °C for subsequent centralized analysis. Under transvaginal ultrasound guidance, the follicular fluid (FF) from the dominant follicle was gently and thoroughly aspirated using a 10-mL syringe, then maintained at steady temperature conditions (37 °C) 
Hormonal measurements in serum and FFs
Blood samples obtained on d3 and dOPU were assayed for AMH, progesterone and estradiol. Serum AMH levels were determined using a "second generation" enzyme-linked immunosorbent assay (reference A16507; Immunotech Beckman Coulter Laboratories, Villepinte, France). Intra-and interassay coefficients of variation were <6% and <10%, respectively, lower detection limit at 0.13 ng/mL, and linearity up to 21 ng/mL for AMH. Serum progesterone and estradiol levels were determined by an automated multi-analysis system using a chemiluminescence technique (Advia-Centaur, Bayer Diagnostics, Puteaux, France). For progesterone, lower detection limit was 0.1 ng/mL, linearity up to 60 ng/mL, and intra-and interassay coefficients of variation were 8% and 9%, respectively. For estradiol, lower detection limit was 15 pg/mL, linearity up to 1,000 pg/mL, and intra-and interassay coefficients of variation were 8% and 9%, respectively. Conversion factor to SI units are 7.14 for AMH, 3.18 for progesterone, and 3.67 for estradiol.
For AMH, progesterone, and estradiol assays in the FF, we used similar methodology as described above. To avoid possible bias due to FF volume variability, hormone concentrations in the FF were adjusted to its protein content, as reported elsewhere (14, 16) . Proteins were measured according to the conventional Biuret reaction (17) using an automated multi-analysis system (AU640, Olympus, Rungis, France). FF hormone levels were expressed as ng/g of protein for both AMH and progesterone and mg/g of protein for estradiol.
Ultrasonographic measurements
Ultrasonographic measurements were performed using a 5.0-9.0 MHz multi-frequency transvaginal probe (Voluson 730 Expert, General Electric Medical Systems, Paris, France) according to a methodology previously described (8, 9) . In brief, on d3, all antral follicles that measured 3-10 mm in mean diameter were carefully counted in both ovaries. On the day of hCG administration, the size of the dominant follicle was the mean of two orthogonal diameters. (AMH </=1.0 ng/mL, n=31), average-d3 (AMH 1.1-2.0 ng/mL, n=45), and high-d3 (AMH >2.0 ng/mL, n=42); serum dOPU AMH levels determined 3 other distinct groups: low-dOPU (AMH </=1.0 ng/mL, n=39), average-dOPU (AMH 1.1-2.0 ng/mL, n=33), and high-dOPU (AMH >2.0 ng/mL, n=46); and FF AMH levels determined 3 additional groups: low-dOPU (AMH </=50.0 ng/g of protein, n=35), average-dOPU (AMH 50.1-100.0 ng/g of protein, n=40), and high-dOPU (AMH >100.0 ng/g of protein, n=43).
Definition of AMH groups
Statistics
T h e m e a s u r e o f c e n t r a l t e n d e n c y u s e d w a s t h e m e a n a n d t h e m e a s u r e o f v a r i a b i l i t y w a s the standard error. Medians and ranges were used when normality of data distribution could not be ascertained. Comparisons between continuous variables from the low, average, and high AMH groups were performed using ANOVA when data distribution was normal or the Kruskal-Wallis test when normality could not be confirmed. To determine the respective influence of different independent variables such as ages, number of antral follicle count, hormonal values on pregnancy and implantation rates we used binomial logistic regression and results were expressed as P and 95%
confidence intervals (CI). Paired comparisons were made with the paired Student's t-test or the Wilcoxon signed rank test when appropriate. Relationship between two continuous variables was assessed by correlation when they were independent from each other and by simple regression when there was a dependency relationship. The Spearman's test was used to determine if coefficients of correlation (r) were significantly different from zero. The present study was powered to detect anticipated differences of 25% in embryo implantation rates at >80% power at 0.05 significance level.
A P value <0.05 was considered statistically significant.
Results
Patient characteristics, cycle monitoring and embryology data
Population characteristics in the low, average, and high serum and FF AMH groups are summarized in Table 1 . As mentioned, women's ages, BMIs, menstrual cycle lengths, and indications for IVF-ET were comparable in the 3 sets of AMH groups (d3, dOPU, FF). In line with this, neither serum nor FF AMH levels were significantly correlated with women's ages, BMIs, menstrual cycle lengths. Overall, on cycle day 3, median antral follicle (3-10 mm) count was 9 (range: 1-24). As expected, this measure was positively correlated with AMH levels on d3 (r=0.74; P <0.0001), dOPU (r=0.71; P <0.0001), and in the FF (r=0.29; P <0.002).
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Cycle monitoring and embryology data in the low, average, and high serum and FF AMH groups are presented in Table 2 . The total dose of hMG used for maintaining dominant follicle growth was similar irrespective of AMH levels in the serum and FF. It is noteworthy that the time necessary to achieve follicle maturation (>16 mm in diameter) was longer in patients showing higher serum d3
AMH. Indeed, the day of hCG administration was positively correlated with serum AMH levels on d3 (r=0.31; P <0.001) and on dOPU (r=0.29; P <0.001), but not with FF AMH levels. As serum AMH levels on d3 (r=0.29; P <0.003) and on dOPU (r=0.26; P <0.008) were correlated with the day in which GnRH antagonist-hMG treatment was started but not with the remaining time required to reach follicle maturation, it is possible that the slower follicular growth in patients having higher serum AMH levels occurred exclusively before GnRH antagonist-hMG treatment. Moreover, on the day of hCG administration, the mean size of the dominant follicle and serum estradiol levels were comparable in the 3 sets of AMH groups and were not correlated with serum or FF AMH levels.
We observed a decrease in the prevalence of oocyte retrieval failure from the low to the high FF AMH groups, irrespective of the number of follicular flushings performed. This phenomenon was not observed in the d3 and dOPU AMH groups. Fertilization rates and the prevalence of top quality embryos available remained comparable in the 3 sets of groups.
Hormonal data
Overall fluctuations of serum AMH, progesterone, and estradiol levels from d3 to dOPU and their absolute FF concentrations are illustrated in Figure 1 . Whereas progesterone and estradiol levels increased significantly (P <0.0001), median AMH levels remained steady between d3 at 1.56 ng/mL (range: 0.13-7.26) and dOPU at 1.50 ng/mL (range: 0.13-6.96). Further, we observed, on dOPU, a positive correlation between serum and FF levels of AMH (r=0.47; P <0.0001), progesterone (r=0.53; P <0.0001), and estradiol (r=0.37; P <0.0001). In addition, FF AMH levels were negatively correlated with FF progesterone (r=-0.27; P <0.0004) and estradiol (r=-0.21; P <0.03) levels. In contrast, serum AMH, progesterone, and estradiol levels were correlated neither on d3 nor on dOPU.
Further, serum AMH levels (d3 and dOPU) and FF AMH levels were correlated with early antral follicle counts on d3 (r=0.75; P <0.0001; r=0.71; P <0.0001, and r=0.29; P <0.002, respectively).
Incidentally, as expected, before adjustment of values to protein content, AMH was roughly 2.5 fold as concentrated in the FF of preovulatory follicles as in the serum on dOPU (3.82 ng/mL versus 1.50 ng/mL, respectively).
Clinical pregnancy, ongoing pregnancy, and implantation rates
Clinical pregnancy, ongoing pregnancy, and embryo implantation rates are presented in Figure 2 . As shown, clinical pregnancy (gestational sac observed at ultrasound scans at around 7 weeks of amenorrhea), ongoing pregnancy (>12 weeks of amenorrhea) rates per oocyte retrieval as well as embryo implantation rates (total number of gestational sacs x 100/total number of embryos 
Discussion
This study used the clinical model of monodominant follicle IVF-ET to determine whether AMH production by a single preovulatory follicle, assessed by FF AMH measurements, is positively related to the fate of the ensuing oocyte and embryo. Although peripheral AMH levels have hitherto been shown to reflect quantitatively the available antral follicle pool (8,7,10,11), a qualitative relationship between AMH production and follicle competence is also conceivable.
The present results support the hypothesis that a direct link exists between aptitude of granulosa cells to produce AMH and functional quality of the oocyte, as reflected by its competence to become an embryo endowed with adequate implantation potential. This striking relationship implies a number of cellular mechanisms. First, it is possible that granulosa cell metabolism and embryogenic competence of the oocyte are interrelated. Indeed, some previous studies have shown that the degree of apoptosis of both mural and cumulus granulosa cells negatively affects the developmental competence of the oocyte (18, 19) . In agreement with this, atretic human (6) and animal (4,13) follicles do not express AMH. In addition, a plethora of studies have identified a relationship between granulosa cell by-products measured in pooled FF, such as steroids, glycoproteins, proteolytic enzymes, etc., and oocyte/embryo outcome (16, (20) (21) (22) (23) (24) . Furthermore, growing evidence indicates that, in preovulatory follicles, the oocyte directly activates several physiological processes that occur in its surrounding granulosa cells, including plasminogen activator production (25) , and LH receptor (27) , kit ligand (27) , and AMH (28) gene expression. Incidentally, the observation that AMH mRNA expression is lower in mural than in cumulus granulosa cells (29) is in keeping with this hypothesis.
Moreover, we observed a remarkable lack of variation of serum AMH levels between two distinct points in the menstrual cycle (d3 and dOPU). This finding corroborates the hypothesis that circulating AMH levels remain steady throughout the cycle, probably due to multi-staged follicular production (4-6) and presumable FSH-independence (2,3) of AMH. In addition, in contrast to FF AMH concentrations, we failed to relate peripheral AMH levels on d3 or dOPU with embryo implantation. Accordingly, the incidence of oocyte retrieval failure -a phenomenon that has been attributed to follicle quality defects (30)-was related with FF but not serum AMH levels. The differential predictability of FF versus serum AMH levels may be explained by the fact that circulating AMH levels reflect quantitatively the whole pool of AMH-producing follicles but are less effective to discriminate per-follicle AMH production. In keeping with this hypothesis is our observation that antral follicle counts are more strongly related to serum AMH levels than FF AMH levels as well as the conflicting literature on the possible link between peripheral AMH levels and embryo implantation (12, 31) . Finally, our observation of a positive correlation between serum AMH levels (d3 and dOPU) and the time necessary to achieve follicle maturation (>16 mm in diameter), mainly due to a shorter time to dominance in low AMH patients, is in conformity with the putative reduction in the follicular phase length in ovarian-aged women (32) .
It is also noteworthy that the negative impact of low per-follicle AMH production on pregnancy and implantation outcome could not be anticipated by the analysis of oocyte fertilization and top-quality embryo rates. Indeed, oocyte fertilization aptitude and embryo morphology remained statistically similar among FF or serum AMH groups, though a trend for better quality embryos was noted in high AMH groups. Given that serum AMH levels have been recently associated with embryo morphology (33) , this issue deserve further confirmation in adequately powered studies.
The present data indicated a negative relationship between AMH and steroid levels in the FF. Although the exact reasons for this phenomenon remain unknown, the reported inhibiting effect of AMH on aromatase activity and estrogen production (34) constitutes a plausible explanation for the negative correlation between FF AMH and estradiol levels. Further, the remarkable negative correlation between FF AMH and progesterone concentrations confirm our previous results (14) and may be explained by at least two mechanisms. On the one hand, AMH may be implicated in the regulation of progesterone production by the preovulatory follicle. Accordingly, Kim et al. (35) have previously demonstrated that the administration of recombinant human AMH to cultured luteinized granulosa cells inhibits their basal and epidermal growth factor (EGF)-stimulated progesterone production. On the other hand, luteinization itself may lead to an additional decrease of AMH production by the granulosa cells. This hypothesis is strengthened by the reduced expression of AMH and its type II receptor mRNA in corpora lutea as compared to small or large antral follicles from rats (4) , and the decline in serum AMH levels observed after hCG administration in controlled ovarian hyperstimulated cycles (36) . The mechanisms underlying the decrease of AMH production by luteinized follicles and its physiological role remain unclear. Yet, the present results are in line with
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In conclusion, the results of the present study indicate that FF AMH concentrations are strongly and positively associated with embryo implantation. They suggest that FF AMH levels reflect granulosa cell functioning and oocyte health better than do serum AMH levels, and may constitute an alternative marker of ovarian ageing. In addition, by extrapolation, FF AMH measurements should help to distinguish the embryos that are the most likely to achieve implantation in IVF-ET conducted in stimulated cycles. Indeed, embryo selection is a precondition to improve outcome of IVF-ET in stimulated cycles without increasing multiple pregnancy rates. This issue is of special interest as the present investigation failed to find any significant difference in the morphological scoring of embryos originated from high or low AMH-producing follicles. Yet, additional prospective studies are necessary to challenge the hypothesis that FF AMH concentrations are useful to assist the selection of the best embryos to transfer. Note that, contrary to serum progesterone and estradiol levels, which showed an expected significant increase (P <0.0001), serum AMH levels remained steady from d3 to dOPU. Gray box-and-whiskers illustrate FF hormone levels, in particular, the residual yet sizeable AMH production by follicles having undergone preovulatory maturation and luteinization. Note: conversion factor to SI units are 7.14 for AMH, 3.18 for progesterone, and 3.67 for estradiol.
Legends
Figure 2
Clinical pregnancy (gestational sac observed at ultrasound scans at around 7 weeks of amenorrhea; gray bars), ongoing pregnancy (>12 weeks of amenorrhea; black bars) rates per oocyte retrieval as well as embryo implantation rates (total number of gestational sacs x 100/total number of embryos transferred; white bars) in the 3 AMH concentration groups. Notice that all 3 IVF-ET outcome parameters increased dramatically from the low to the high FF AMH groups (C panel; P <0.002, P <0.01, P <0.001, respectively) but remained similar in the 2 sets of serum AMH groups (d3 and dOPU; A and B panels, respectively). Note: conversion factor to SI units are 7.14 for AMH, 3.18
for progesterone, and 3.67 for estradiol. 
